2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1176

Interleukin-37 Prevents New-Onset Joint Inflammation but Does Not Inhibit Existing Experimental Arthritis

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1189

Internal Medicine Subspecialty Fellows’ Attitudes Towards Teaching and Learning How to Teach: A Needs Assessment

Education Poster I

9:00AM-11:00AM: Abstract Number: 1961

Interobserver Agreement on Ultrasonographic and Magnetic Resonance Angiography Findings in Patients with Large Vessel Vasculitis

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1983

Interspinous Bursitis Evaluation By Ultrasound Is Very Useful for Diagnosis of Polymyalgia Rheumatica

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1362

Investigating the Role of Dendritic Cell Maturation & T Cell Activation within the Inflamed Synovium in Rheumatoid Arthritis

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1212

Investigation of Vitamin D Supplement Use, Rheumatoid Arthritis-Related Autoimmunity and Joint Signs Among Those at Increased Risk for the Development of Rheumatoid Arthritis

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1303

Is MRI More Sensitive Than Conventional Radiographs to Detect Hand Osteoarthritis Progression over 5 Years Follow-up?

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1316

Is MRI of Use in Identifying Which Undifferentiated Arthritis Patients Will Develop RA?

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1881

Is the Presence of Esophageal Dilation a Poor Prognostic Factor in Dilated Interstitial Lung Disease Associated with Systemic Sclerosis?

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1793

Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1401

Is There Any Difference Between Autoimmune or Hemato-Oncology Etiology of Macrophage Activation Syndrome?

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1736

Is There Evidence to Support Replacing Conventional AP Pelvis Radiographs with Dedicated Sacroiliac Joint Views for the Diagnosis of Sacroiliitis?

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1523

Ischemia Modified Albumin Levels in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1928

Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 1582

Joint Damage Associated with Loss of Body Mass in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].